400-21-0725
| 规格 | 目录价格 | 上海 | 安徽 | 武汉 | 成都 | 北方 | 深圳 | 会员价格 | 数量 |
|---|---|---|---|---|---|---|---|---|---|
| 5mg | ￥ ǃŇŇñŇŇ | > | -- | -- | -- | -- | -- | ￥ ǃŇŇñŇŇ | - + |
| mg | ￥ ŨŨŇŇñŇŇ | > | -- | -- | -- | -- | -- | ￥ ŨŨŇŇñŇŇ | - + |
| 25mg | ￥ ǛŇŇŇñŇŇ | > | -- | -- | -- | -- | -- | ￥ ǛŇŇŇñŇŇ | - + |
| 50mg | ￥ ĽĢŇŇñŇŇ | > | -- | -- | -- | -- | -- | ￥ ĽĢŇŇñŇŇ | - + |
| 0mg | ￥ ƞƖŇƖñŇŇ | > | -- | -- | -- | -- | -- | ￥ ƞƖŇƖñŇŇ | - + |
| 250mg | ￥ ĢǃĢǛñŇŇ | > | -- | -- | -- | -- | -- | ￥ ĢǃĢǛñŇŇ | - + |
| 500mg | 请询价 | -- | -- | -- | -- | -- | -- | -- | - + |
| 1g | 请询价 | -- | -- | -- | -- | -- | -- | -- | - + |
| 5g | 请询价 | -- | -- | -- | -- | -- | -- | -- | - + |
19.22
[1]. Dabigatran
[2]. Preetpal Singh Sidhu,Aiye Liang, Akul Y. Mehta,et al. Rational Design of Potent, Small, Synthetic Allosteric Inhibitors of Thrombin. J Med Chem. 2011; 54(15): 5522-551.
[]. Santiago Redondo, Maria-Paz Martínez, Marta Ramajo, et al. Pharmacological basis and clinical evidence of dabigatran therapy. J Hematol Oncol. 2011; 4: 5.
[4]. Simon Michaelis, Anett Marais, Anna K. Schrey, et al. Dabigatran and Dabigatran Ethyl Ester: Potent Inhibitors of Ribosyldihydronicotinamide Dehydrogenase (NQO2). J. Med. Chem., 2012, 55 ():94-944
[5]. Stefan Blech, Thomas Ebner, Eva Ludwig-Schwellinger,et al. The Metabolism and Disposition of the Oral Direct Thrombin Inhibitor, Dabigatran, in Humans. DMD ,200 , 6 (2) 6-99
H02-H15-H19-H5
P261-P264-P270-P271-P20-P02+P52-P04+P40-P05+P51+P-P0-P62+P64-P40+P2-P405-P501
12579 现货
￥ ŨŇĽŇñŇŇ -50mg
1276 货期咨询
￥ ǷǛŇñŇŇ -5mg
22157 货期咨询
22205 货期咨询
2215 货期咨询
2075415 货期咨询
9199 货期咨询
￥ ŨĽĽüñŇŇ -0mg
2071969 货期咨询
20726 货期咨询
20729 货期咨询
沪ICP备17019645号
